Read Time:1 Minute, 25 Second


On August 30, 2021, the WHO classified the SARS-CoV-2 Mu variant (B.1.621 lineage) as a new variant of interest. The WHO defines “comparative assessment of virus characteristics and public health risks” as primary action in response to the emergence of new SARS-CoV-2 variants. Here, we demonstrate that the Mu variant is highly resistant to sera from COVID-19 convalescents and BNT162b2-vaccinated individuals. Direct comparison of different SARS-CoV-2 spike proteins revealed that Mu spike is more resistant to serum-mediated neutralization than all other currently recognized variants of interest (VOI) and concern (VOC). This includes the Beta variant (B.1.351) that has been suggested to represent the most resistant variant to convalescent and vaccinated sera to date (e.g., Collier et al, Nature, 2021; Wang et al, Nature, 2021). Since breakthrough infection by newly emerging variants is a major concern during the current COVID-19 pandemic (Bergwerk et al., NEJM, 2021), we believe that our findings are of significant public health interest. Our results will help to better assess the risk posed by the Mu variant for vaccinated, previously infected and naïve populations.

Competing Interest Statement

The authors have declared no competing interest.

Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera
Keiya Uriu, Izumi Kimura, Kotaro Shirakawa, Akifumi Takaori-Kondo, Taka-aki Nakada, Atsushi Kaneda, The Genotype to Phenotype Japan (G2P-Japan) Consortium, So Nakagawa, Kei Sato
bioRxiv 2021.09.06.459005; doi:

Average Rating

5 Star
4 Star
3 Star
2 Star
1 Star

Leave a Reply